As of November 9, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Centessa Pharmaceuticals plc. The largest reported stake is Avoro Capital Advisors LLC's, at 7.39%. 20 filings are on record since August 12, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Centessa Pharmaceuticals plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Pentwater Capital Management LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Index Ventures Life Vi (Jersey) L.P. · Percent: 0% · SCHEDULE 13G/A
- · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Medicxi Growth I LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-04
- · Reporting person: Fmr LLC · Sole voting: 1,800 · Shared voting: 0 · Sole dispositive: 1,800 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-08
Centessa Pharmaceuticals plc has 20 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of ordinary shares, nominal value 0.002 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 7.39% | 11,430,455 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| 5% | 7,366,818 | SCHEDULE 13D/A, 2025-11-28 | 2025-11-25 | |
| Adage Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Fmr LLC | 0% | 1,800 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
| Pentwater Capital Management LP | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Farallon Capital Management, L.L.C. | 0% | 0 | SCHEDULE 13D/A, 2026-06-26 | 2026-06-24 |
| Medicxi Growth I LP | 0% | 0 | SCHEDULE 13G/A, 2026-08-04 | 2026-06-30 |
| Index Ventures Life Vi (Jersey) L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Centessa Pharmaceuticals plc and the warning signs.
Free to see. No signup.
Keep reading
More on Centessa Pharmaceuticals plc and the records around it.
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- FARALLON CAPITAL MANAGEMENT, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Pentwater Capital Management LP also filed stake reports on 20 other companies: AMC Entertainment Holdings, Inc. (Aug 2026), Caesars Entertainment, Inc. (Aug 2026), Core Scientific, Inc. (Aug 2026)
Watch Centessa Pharmaceuticals plc
Get an email when Centessa Pharmaceuticals plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Centessa Pharmaceuticals plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Centessa Pharmaceuticals plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Centessa Pharmaceuticals plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Adage Capital Management, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| Robert Atchinson | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| Phillip Gross | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| Fmr LLC | 1,800 | 0 | 1,800 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| Abigail P. Johnson | 0 | 0 | 1,800 | 0 | SCHEDULE 13G/A, 2026-07-08 |
| Pentwater Capital Management LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Matthew Halbower | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Management, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Dapice Joshua J. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Dreyfuss, Philip D. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Dunn Hannah E. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Gehani, Varun N. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Giauque, Nicolas | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Husen, Avner A. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Kim, David T. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Linn, Michael G. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Luo Patrick (Cheng) | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Roberts, Jr., Thomas G. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Saito Edric C. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Short Daniel S. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Spokes, Andrew J. M. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Warren, John R. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Wehrly, Mark C. | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-26 |
| Medicxi Growth I LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
The latest filing identifies Centessa Pharmaceuticals plc by CUSIP 152309100 and gives its principal executive office as 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 6.29% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 7% | SCHEDULE 13G |
| 2025-11-13 | Adage Capital Management, L.P. | 7.48% | SCHEDULE 13G/A |
| 2025-11-14 | Avoro Capital Advisors LLC | 8.06% | SCHEDULE 13G |
| 2025-11-17 | General Atlantic Cooperatief U.A. | 6.6% | SCHEDULE 13D/A |
| 2025-11-28 | General Atlantic Cooperatief U.A. | 5% | SCHEDULE 13D/A |
| 2026-02-05 | Fmr LLC | 9.9% | SCHEDULE 13G/A |
| 2026-02-06 | Fmr LLC | 12.2% | SCHEDULE 13G/A |
| 2026-02-17 | Avoro Capital Advisors LLC | 9.97% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 7.5% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 5.77% | SCHEDULE 13G/A |
| 2026-05-15 | Avoro Capital Advisors LLC | 7.39% | SCHEDULE 13G/A |
| 2026-05-15 | Pentwater Capital Management LP | 5.3% | SCHEDULE 13G |
| 2026-06-24 | Farallon Capital Management, L.L.C. | 6.1% | SCHEDULE 13D |
| 2026-06-26 | Farallon Capital Management, L.L.C. | 0% | SCHEDULE 13D/A |
| 2026-07-08 | Fmr LLC | 0% | SCHEDULE 13G/A |
| 2026-08-04 | Medicxi Growth I LP | 0% | SCHEDULE 13G/A |
| 2026-08-12 | Adage Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-08-14 | Pentwater Capital Management LP | 0% | SCHEDULE 13G/A |
| 2026-08-14 | Index Ventures Life Vi (Jersey) L.P. | 0% | SCHEDULE 13G/A |
Questions about who owns Centessa Pharmaceuticals plc
Who owns Centessa Pharmaceuticals plc?
On this page, 2 holders' latest ownership filings report 5% or more of Centessa Pharmaceuticals plc: Avoro Capital Advisors LLC (7.39%, Schedule 13G/A, filed 2026-05-15) and General Atlantic Cooperatief U.A. (5%, Schedule 13D/A, filed 2025-11-28).
Who are the largest shareholders of Centessa Pharmaceuticals plc?
By the share each holder's latest filing reports, the largest holders of Centessa Pharmaceuticals plc on this page are Avoro Capital Advisors LLC (7.39%) and General Atlantic Cooperatief U.A. (5%).
When did Avoro Capital Advisors LLC buy into Centessa Pharmaceuticals plc?
The filings give report dates, not purchase dates. The earliest filing from Avoro Capital Advisors LLC on this page is the Schedule 13G, filed 2025-11-14, reporting 8.06%; its latest, Schedule 13G/A filed 2026-05-15, reports 7.39%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 20 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Centessa Pharmaceuticals plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 24, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Centessa Pharmaceuticals plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.